CN101652345A - 新型蛋白激酶调节剂和其治疗应用 - Google Patents

新型蛋白激酶调节剂和其治疗应用 Download PDF

Info

Publication number
CN101652345A
CN101652345A CN200780050587A CN200780050587A CN101652345A CN 101652345 A CN101652345 A CN 101652345A CN 200780050587 A CN200780050587 A CN 200780050587A CN 200780050587 A CN200780050587 A CN 200780050587A CN 101652345 A CN101652345 A CN 101652345A
Authority
CN
China
Prior art keywords
compound
halogen
ptk
compounds
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200780050587A
Other languages
English (en)
Chinese (zh)
Inventor
哈达斯·路维尼
亚历山大·利维斯兹奇
利拉奇·斯泰纳
莉薇特丽·萨森
艾里斯·本-大卫
阿维·魏斯伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novotyr Therapeutics Ltd
Original Assignee
Novotyr Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novotyr Therapeutics Ltd filed Critical Novotyr Therapeutics Ltd
Publication of CN101652345A publication Critical patent/CN101652345A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/40—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C327/44—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
CN200780050587A 2006-12-04 2007-12-04 新型蛋白激酶调节剂和其治疗应用 Pending CN101652345A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87251106P 2006-12-04 2006-12-04
US60/872,511 2006-12-04

Publications (1)

Publication Number Publication Date
CN101652345A true CN101652345A (zh) 2010-02-17

Family

ID=39111493

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780050587A Pending CN101652345A (zh) 2006-12-04 2007-12-04 新型蛋白激酶调节剂和其治疗应用

Country Status (8)

Country Link
US (1) US8058309B2 (https=)
EP (1) EP2125712B1 (https=)
JP (1) JP2010511694A (https=)
CN (1) CN101652345A (https=)
AU (1) AU2007330333A1 (https=)
BR (1) BRPI0719708A2 (https=)
CA (1) CA2671632A1 (https=)
WO (1) WO2008068751A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2758016A1 (en) * 2008-06-05 2009-12-10 Novotyr Therapeutics Ltd. Novel modulators of protein kinase signaling
ES2566673T3 (es) 2010-12-27 2016-04-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Derivados 2-(2-feniletenilo)-1,3-benzotiazol útiles para el tratamiento del cáncer
WO2012117396A1 (en) 2011-03-01 2012-09-07 Novotyr Therapeutics Ltd Tyrphostin derivative in combination with cytotoxic compounds for treating cancer
EP3021944B1 (en) * 2013-07-14 2018-12-19 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Igf-1r signaling pathway inhibitors useful in the treatment of neurodegenerative diseases
CN107250108B (zh) * 2015-02-05 2020-11-27 特尔诺沃有限公司 用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合
WO2019097503A1 (en) 2017-11-16 2019-05-23 Tyrnovo Ltd. Combinations of irs/stat3 dual modulators and anti pd-1/pd-l1 antibodies for treating cancer
WO2019246273A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
CN115466205B (zh) * 2021-11-04 2023-10-24 特尔诺沃有限公司 分离的3-（2-溴-3,4-二羟基-苯基）-n-（3,4,5-三羟基-苄基）-硫代丙烯酰胺的反式异构体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
WO1995024190A2 (en) * 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
US20040197335A1 (en) * 2001-06-14 2004-10-07 Shimon Slavin Non-myeloablative tolerogenic treatment with tyrphostins
CA2466928A1 (en) * 2001-12-10 2003-07-03 Yansheng Du Treatment of neurodegenerative and cardiovascular disorders
WO2003101927A1 (en) * 2002-05-31 2003-12-11 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease

Also Published As

Publication number Publication date
US20100056635A1 (en) 2010-03-04
AU2007330333A1 (en) 2008-06-12
CA2671632A1 (en) 2008-06-12
EP2125712A1 (en) 2009-12-02
EP2125712B1 (en) 2014-07-23
BRPI0719708A2 (pt) 2014-02-18
US8058309B2 (en) 2011-11-15
JP2010511694A (ja) 2010-04-15
WO2008068751A1 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
CN101652345A (zh) 新型蛋白激酶调节剂和其治疗应用
KR101879908B1 (ko) 퀴놀릴기를 함유하는 히드록삼산계 화합물 및 이의 제조방법, 및 이를 함유하는 약물 조성물 및 이의 용도
TWI808958B (zh) 涉及二芳基巨環化合物之組合療法
JP6463366B2 (ja) １２−リポキシゲナーゼ阻害物質としての４−（（２−ヒドロキシ−３−メトキシベンジル）アミノ）ベンゼンスルホンアミド誘導体
CA3130568A1 (en) Novel pyrido[3,4-d]pyrimidin-8-one derivative having protein kinase inhibitory activity, and pharmaceutical composition for preventing, alleviating, or treating cancer, comprising same
SK287259B6 (sk) Deriváty amidov N-arylantranilovej kyseliny, farmaceutický prostriedok, ktorý ich obsahuje, spôsob ich prípravy a ich použitie ako inhibítorov VEGF receptora tyrozínkinázy
TW201728583A (zh) 氨基噻唑化合物及其用途
EP3272742B1 (en) Histone deacetylase inhibitor, and preparation method and use thereof
US8637575B2 (en) Modulators of protein kinase signaling
TW201236684A (en) Pharmaceutically acceptable salts of (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide, preparation process and pharmaceutical use there of
WO2004013091A2 (en) 4-anilido substituted quinazolines and use thereof as inhibitors of epidermal growth factor receptor kinases
JPWO2006104161A1 (ja) ｃ−Ｍｅｔ自己リン酸化阻害作用を有するチエノピリジン誘導体、キノリン誘導体、およびキナゾリン誘導体
CA2958741C (en) Quinazoline derivatives
US20070149535A1 (en) Protein kinase inhibitors
WO2015021894A1 (zh) 新型羟肟酸衍生物及其医疗应用
US20120083528A1 (en) Novel protein kinase modulators and therapeutic uses thereof
US9073880B2 (en) 2-(2-phenylethenyl) 1,3-benzodiazepine derivatives useful for the treatment of cancer
US20050143430A1 (en) Catechol bioisosteres
CN111362871B (zh) 取代的吡啶-2-甲酰胺类化合物及其用途
KR102205619B1 (ko) 신규한 인다졸 유도체 화합물 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
KR101018791B1 (ko) 세포외 신호조절 키나제의 활성을 저해하는타이오옥소-타이아졸리딘-온 유도체 또는 이의 약학적으로허용가능한 염을 유효성분으로 함유하는 암 또는 심혈관계질환의 예방 또는 치료용 조성물
RU2801302C2 (ru) Производные циклического иминопиримидина в качестве ингибиторов киназ
US20240425452A1 (en) Isolated trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-n-(3,4,5-trihydroxy-benzyl)-thioacrylamide
TWI457323B (zh) 組織蛋白去乙醯酶抑制劑
KR101464280B1 (ko) 클로라이드 채널 차단제로 유용한 화합물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100217